NY-CLOUDREACH
28.1.2021 15:02:31 CET | Business Wire | Press release
Cloudreach , the leading independent multi-cloud services company, today announced the launch of Cloudreach DevOps as a Service. This new offering combines Cloudreach development and operations, making them available ‘as a Service’ via a simple and flexible subscription model. DevOps as a Service is the first of its kind in the market, and fundamentally changes how cloud IT services are consumed to make it easy for enterprises to adopt cloud native technologies and practices.
Dave Chapman, Head of Strategy and Professional Services at Cloudreach, said: “Cloudreach DevOps as a Service brings a DevOps and cloud engineering skill set to any enterprise, whether they are new to the cloud or far along their modernization journey. Companies that undergo cloud transformation are better able to adapt to disruption, explore and innovate faster. This service helps technology leaders get the right skills in place, at the right time, and scale up and down to suit their changing requirements.”
Cloud acceleration
DevOps is a set of practices that combines software development and IT operations, removing the barriers between these traditionally siloed teams. Under a DevOps model, development and operations teams work together across the entire software application life cycle, from development and test through deployment to operations.
More than a decade after the introduction of cloud computing, many enterprises still find themselves suffering from the symptoms of legacy IT and legacy partners. Cloudreach DevOps as a Service makes cloud outsourcing easy by providing flexible engineering squads as a monthly subscription service. The new offering is designed to help technology leaders accelerate their cloud initiatives, embrace true DevOps within their teams, and help their organizations become more cloud native.
Cloudreach DevOps as a Service provides a core DevOps team that can be augmented to perform architecture, platform development, data engineering, application UX and product management roles, all as a unified service. As business priorities or backlogs change, the flexible nature of the service means customers can swap out squad members and scale the team up and down as needed, within a single statement of work. The minimum squad size includes two resources and 80 hours per month, with a minimum contract commitment of three months.
Cloudreach squads have a radical focus on trend improvement and platform evolution. They can help launch new products, accelerate and scale business initiatives, facilitate stronger collaboration with digital teams, or support key applications and infrastructure.
James Dunn, Head of Cloud Platform Development at Cloudreach, said: “Over its 10-year history, Cloudreach has delivered some of the largest and most successful cloud engineering projects in the world. Now we are bringing Cloudreach's cloud native expertise to market in a flexible subscription model.”
- ENDS -
About Cloudreach
Cloudreach is a leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation.
With more than 10 years of cloud native experience, we've built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our services, visit cloudreach.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom